Fish represented Coherus before the PTAB.

On June 9, 2017, the Patent Trial and Appeal Board ruled in favor of Coherus’ petitions for inter partes review (IPR) of AbbVie’s U.S. Patent 9,073,987 (‘987 Patent) and U.S. Patent 9,017,680 (‘680 Patent). The PTAB’s decision invalidates all claims of the patents that were directed to a method of treating rheumatoid arthritis.  Back on May 16, Coherus prevailed at the PTAB in a similar IPR proceeding involving AbbVie’s U.S. Patent 8,889,135 (‘135 Patent).

These decisions are the first to invalidate core AbbVie patents covering the blockbuster drug HUMIRA in the United States. To read the press release on the ‘135 Patent decisions, click here.

HUMIRA® is a registered trademark of AbbVie Biotechnology, Ltd.

[View source.]